[
    [
        {
            "time": "2020-01-01",
            "original_text": "CRO&CDMO投研体系之数据跟踪(系列四)：2020H1回顾与前瞻 疫情背景下中国企业竞争优势凸显",
            "features": {
                "keywords": [
                    "疫情",
                    "竞争优势",
                    "CRO",
                    "CDMO"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "CRO&CDMO投研体系之数据跟踪(系列四)：2020H1回顾与前瞻 疫情背景下中国企业竞争优势凸显",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2020-09-15",
            "original_text": "泰格医药(03347.HK)拟参与认购嘉和生物首次公开发行股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "嘉和生物",
                    "IPO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(03347.HK)拟参与认购嘉和生物首次公开发行股份",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-16",
            "original_text": "泰格医药(03347.HK)拟参与投资泰誉三期医疗器械基金",
            "features": {
                "keywords": [
                    "泰格医药",
                    "医疗器械",
                    "基金"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(03347.HK)拟参与投资泰誉三期医疗器械基金",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-20",
            "original_text": "医药行业周报：医保目录调整逐步进行 冠状动脉支架首批纳入器械国采",
            "features": {
                "keywords": [
                    "医保目录",
                    "冠状动脉支架",
                    "器械国采"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药行业周报：医保目录调整逐步进行 冠状动脉支架首批纳入器械国采",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-10-01",
            "original_text": "泰格医药(300347.SZ)拟2200万美元作为基石投资者参与认购嘉和生物(06998)股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "嘉和生物",
                    "IPO",
                    "基石投资者"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)拟2200万美元作为基石投资者参与认购嘉和生物(06998)股份",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-10-02",
            "original_text": "泰格医药：子公司拟作为基石投资者认购嘉和生物港股IPO股份",
            "features": {
                "keywords": [
                    "泰格医药",
                    "嘉和生物",
                    "港股IPO",
                    "基石投资者"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：子公司拟作为基石投资者认购嘉和生物港股IPO股份",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-03",
            "original_text": "泰格医药：全资子公司拟以基石投资者身份参与嘉和生物香港首次公开发行",
            "features": {
                "keywords": [
                    "泰格医药",
                    "嘉和生物",
                    "香港IPO",
                    "基石投资者"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：全资子公司拟以基石投资者身份参与嘉和生物香港首次公开发行",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-04",
            "original_text": "泰格医药(300347.SZ)：拟出资2.4亿元参投泰誉三期医疗器械基金",
            "features": {
                "keywords": [
                    "泰格医药",
                    "医疗器械",
                    "基金"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)：拟出资2.4亿元参投泰誉三期医疗器械基金",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-10-05",
            "original_text": "泰格医药(300347.SZ)：子公司拟以基石投资者身份认购嘉和生物H股IPO股票",
            "features": {
                "keywords": [
                    "泰格医药",
                    "嘉和生物",
                    "H股IPO",
                    "基石投资者"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药(300347.SZ)：子公司拟以基石投资者身份认购嘉和生物H股IPO股票",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-10-06",
            "original_text": "早间公告：泰格医药子公司拟参与嘉和生物港股IPO；中航飞机重组方案出炉",
            "features": {
                "keywords": [
                    "泰格医药",
                    "嘉和生物",
                    "港股IPO",
                    "中航飞机",
                    "重组"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "航空"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "早间公告：泰格医药子公司拟参与嘉和生物港股IPO；中航飞机重组方案出炉",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-07",
            "original_text": "国家级混改基金有望近期成立",
            "features": {
                "keywords": [
                    "混改基金",
                    "国家级"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国家级混改基金有望近期成立",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-08",
            "original_text": "医药生物行业日报：估值步入合理区间 关注超跌个股",
            "features": {
                "keywords": [
                    "医药生物",
                    "估值",
                    "超跌个股"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业日报：估值步入合理区间 关注超跌个股",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]